Becton Dickinson's HPV assay was FDA-approved for use with clinician-collected samples in 2018 and received approval for sample self-collection in May.

The firm's HPV assay was FDA-approved for use with clinician-collected samples in 2018 and received approval for sample self-collection in May.

NEW YORK – Natera announced on Wednesday that its Prospera Lung test has received coverage from the US Centers for Medicare and Medicaid Services for single lung transplant patients in the ...

The company's CircleDNA and ACT Genomics businesses are on track to achieve business-unit breakeven in the second half of 2024, it said.

The HemoScreen instrument is a point-of-care five-part differential complete blood count analyzer that is used for rapid testing from a drop of blood.

The company, based outside of Grenoble in the French Alps, together with its partners has received €5 million to pursue the project.

While Congress has protected labs from PAMA cuts via a series of one-year delays, this has locked lab prices at 2016 levels, ...

Called the Coalition for Effective Diagnostics, the organization has called on lawmakers to pass legislation revamping diagnostics regulation, including oversight of LDTs.

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous ...

Last week, readers were most interested in a story about the development of an AI-based method to predict COPD flare-ups before symptoms appear.

According to the DOJ, Osman Syed submitted more than $79 million in fraudulent claims to Medicare and Texas Medicaid for RPP testing.

The company analyzes urine samples using a lateral flow test and optical reader combined with artificial intelligence to predict lung disease exacerbations.